AGNISTABIO
Live / Applied — Second extension granted (statement of use) (as of 11 Nov 2025)
What this means for you
Not registered yet, but its 29 Apr 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98525680
- Mark type
- Stylized text
- Filed
- 29 Apr 2024
- Published for opposition
- 17 Dec 2024
- Attorney of record
- Enshan Hong
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of inflammatory diseases, immune related diseases, disorders and conditions; biological preparations for the treatment of inflammatory diseases, immune related diseases, disorders and conditions; pharmaceutical preparations for the treatment of cancer, tumor, malignancies, and related diseases, disorders, and conditions; biological preparations for the treatment of cancer, tumor, malignancies, and related diseases, disorders, and conditions; pharmaceutical preparations for the treatment of eye diseases; biological preparations for the treatment of eye diseases; pharmaceutical preparations for the treatment of cardiovascular diseases; biological preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of brain disorders; biological preparations for the treatment of brain disorders
- Class 042 — Scientific and technological services: Medical and scientific research in the field of inflammatory diseases, immune related diseases, disorders, and conditions treatment and diagnosis; medical and scientific research in the field of cancer, tumors, malignancies, and related diseases, disorders and conditions treatment and diagnosis; Medical and scientific research in the field of eye diseases, cardiovascular diseases and brain disorders treatment and diagnosis; Clinical research in the field of inflammatory diseases, immune related diseases, disorders, and conditions; Clinical research in the field of cancer, tumors, malignancies, and related diseases, disorders and conditions; Clinical research in the field of eye diseases, cardiovascular diseases and brain disorders, and conditions; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Scientific research and development; Conducting early evaluations in the field of new pharmaceuticals; Research and development of pharmaceutical and biopharmaceutical preparations and medicines; Pharmaceutical and biotechnology products development; Research and development in the pharmaceutical and biotechnology fields; Pharmaceutical and biopharmaceutical research services in the fields of inflammatory diseases, immune related diseases, disorders, and conditions, cancer, tumors, malignancies, and related diseases, disorders, conditions, eye diseases, cardiovascular diseases, and brain disorders; Pharmaceutical and biopharmaceutical research services in the nature of biomarker identification; Pharmaceutical and biopharmaceutical research services, namely, artificial intelligence assisted drug discovery and development services; Software as a service services featuring artificial intelligence software for drug discovery and development; Scientific and technological services and research and design relating thereto in the nature of pharmaceutical research and development; Industrial analysis and research services in the nature of pharmaceutical research and development; Design and development of computer hardware and software
- Class 044 — Medical, beauty and agricultural services: Providing medical information in the field of inflammatory disease, immune related diseases, disorders and conditions prevention, screening, diagnosis and treatment; providing medical information in the field of cancer, tumor, malignancies, and related diseases, disorders, and conditions prevention, screening, diagnosis and treatment; providing medical information in the field of eye diseases, cardiovascular diseases, and brain disorder prevention, screening, diagnosis and treatment
- Class 045 — Legal and security services: Licensing of intellectual property; Licensing of intellectual property in the field of pharmaceuticals; Licensing of intellectual property in the field of medical and scientific technologies; legal services
Owner
- AgnistaBio Inc., Palo Alto, CA, US
- AgnistaBio Inc., Palo Alto, CA, US
Prosecution history
- 12 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Nov 2025 — SOU EXTENSION 2 GRANTED
- 11 Nov 2025 — SOU EXTENSION 2 FILED
- 11 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 03 Apr 2025 — SOU EXTENSION 1 GRANTED
- 02 Apr 2025 — SOU EXTENSION 1 FILED
- 02 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Feb 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 17 Dec 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 17 Dec 2024 — PUBLISHED FOR OPPOSITION
- 11 Dec 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 21 Nov 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 21 Nov 2024 — EXAMINER'S AMENDMENT ENTERED
- 21 Nov 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED